Stephen Flitman, MD
Neurology · Phoenix, AZNPI 1023018223
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 989 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $6,055, 4.3 times the $1,405 reported in 2019.
Across 989 payments — averaging $24.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Biogen$2K
- Novartis$1K
- UCB, Inc.$1K
- Eisai Inc.$1K
- AstraZeneca$875
- plus $15K from 54 others
Across 387 payments — averaging $11,229 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.3M
- Biogen$910K
- Genentech, Inc.$499K
- UCB SA$248K
- Eisai Inc.$221K
- AbbVie$191K
- plus $943K from 16 others
What the payments were for
- Consulting fees$6002%
- Speaking & faculty fees$1401%
- Food & beverage$23,33396%
- Education$3151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,388 in reported general payments places this provider in the 80th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 39 | $170,563 |
| Kesimpta PenOfatumumab | 12 | $116,242 |
| Emgality PenGalcanezumab-Gnlm | 53 | $79,199 |
| NuplazidPimavanserin Tartrate | 12 | $68,873 |
| Nurtec OdtRimegepant Sulfate | 16 | $49,085 |
| RexultiBrexpiprazole | 23 | $47,297 |
| BotoxOnabotulinumtoxina | 27 | $44,357 |
| OngentysOpicapone | 14 | $23,652 |
| UbrelvyUbrogepant | 11 | $16,428 |
| Galantamine ErGalantamine Hbr | 105 | $13,153 |
| Rivastigmine | 57 | $12,709 |
| Memantine Hcl | 225 | $9,085 |
| Donepezil Hcl | 300 | $7,616 |
| Gabapentin | 212 | $6,695 |
| Duloxetine Hcl | 145 | $6,515 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $476 | $170,56339 claims |
| Acadia Pharmaceuticals IncNuplazid | $674 | $68,87312 claims |
| AbbVieBotox, Ubrelvy | $2,609 | $60,78538 claims |
| PfizerNurtec Odt | $779 | $49,08516 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $742 | $47,29723 claims |
| Neurocrine Biosciences, Inc.Ongentys | $578 | $23,65214 claims |
| Upsher-smith Laboratories LLCTopiramate | $83 | $4,559232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 388 neurology providers in Arizona.
Other neurology in Phoenix
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
- Kerry KnievelPhoenix$509K
- Lori TravisPhoenix$406K
- Jeffrey GittPhoenix$275K
- Todd SchwedtPhoenix$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.